European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatitis c, chronic - antivirals for systemic use - incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis c in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - glecaprevir, quantity: 50 mg; pibrentasvir, quantity: 20 mg - granules - excipient ingredients: copovidone; tocofersolan; propylene glycol monocaprylate; colloidal anhydrous silica; croscarmellose sodium; sodium stearylfumarate; purified water; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350; iron oxide yellow - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole mylan pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.aripiprazole mylan pharma is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole mylan pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.

European Union - English - EMA (European Medicines Agency)

bayer ag - telmisartan - hypertension - agents acting on the renin-angiotensin system - hypertensiontreatment of essential hypertension in adults.cardiovascular preventionreduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitis c, chronic - antivirals for systemic use - victrelis is indicated for the treatment of chronic hepatitis-c (chc) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

European Union - English - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - hepatitis c, chronic - antivirals for systemic use - olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult patients.for hepatitis c virus (hcv) genotype specific activity.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - glecaprevir, quantity: 100 mg; pibrentasvir, quantity: 40 mg - tablet, film coated - excipient ingredients: propylene glycol monocaprylate; tocofersolan; croscarmellose sodium; sodium stearylfumarate; copovidone; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350 - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - glecaprevir, quantity: 100 mg; pibrentasvir, quantity: 40 mg - tablet, film coated - excipient ingredients: propylene glycol monocaprylate; tocofersolan; croscarmellose sodium; sodium stearylfumarate; copovidone; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350 - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

United States - English - NLM (National Library of Medicine)

merial, inc. - firocoxib (unii: y6v2w4s4wt) (firocoxib - unii:y6v2w4s4wt) - firocoxib 57 mg - caution: federal law restricts this drug to use by or on the order of a licensed veterinarian. indications: previcox (firocoxib) chewable tablets are indicated for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. contraindications: dogs with known hypersensitivity to firocoxib should not receive previcox.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc - firocoxib (unii: y6v2w4s4wt) (firocoxib - unii:y6v2w4s4wt) - indications: previcox (firocoxib) chewable tablets are indicated for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. contraindications: dogs with known hypersensitivity to firocoxib should not receive previcox.